GcMAFplus: Science-Driven Immune Support

At GcMAFplus, our mission is to offer science-driven solutions that support the body?s natural ability to defend and repair. A key element of our innovation lies in the synergy between two critical components of immune regulation: GcMAF (Gc Macrophage Activating Factor) and the ZEB2 gene, a master regulator of macrophage identity and tumor microenvironment programming.

What Is GcMAF?

GcMAF (Gc Macrophage Activating Factor) is a biologically active glycoprotein derived from the enzymatic cleavage of vitamin D-binding protein (Gc protein). When fully activated, GcMAF binds to macrophage receptors, transforming them from a dormant state into active defenders of the immune system.

These activated macrophages are known as M1 macrophages ? the pro-inflammatory, anti-tumor phenotype responsible for phagocytosis, antigen presentation, and cytokine release. Macrophage activation is essential for initiating immune responses against abnormal or malignant cells.

What Is ZEB2?

ZEB2 (Zinc finger E-box-binding homeobox 2) is a transcription factor involved in regulating immune cell behavior, particularly in the tumor microenvironment. According to the most recent research from the Weizmann Institute of Science (Cancer Cell, 2025), ZEB2 has been identified as a key gene that promotes tumor progression when expressed in macrophages.

Tumor-associated macrophages (TAMs) that express high levels of ZEB2 adopt a tumor-promoting M2 phenotype. Suppressing the expression of ZEB2 reprograms these macrophages into an anti-tumor M1 phenotype, actively fighting cancer.

The Synergy: GcMAFplus and ZEB2

Our GcMAFplus formulations available in transdermal creams and sublingual sprays, activate macrophages at the frontline of the immune system. Upon activation, GcMAF triggers epigenetic changes in macrophages that result in the suppression of ZEB2 expression. This helps convert tumor-supporting M2 macrophages into cancer-fighting M1 macrophages.

In Conclusion:

GcMAFplus activates macrophages, promoting their transformation into M1 macrophages, which are known to exhibit potent anti-tumor activity through phagocytosis, cytokine release, and antigen presentation.

Simultaneously, GcMAFplus suppresses the expression of the ZEB2 gene, preventing the reprogramming of activated macrophages into an M2 phenotype, which is associated with a pro-tumor environment.

This dual action ensures that macrophages maintain their cancer-killing capability and are not reverted to a state that supports tumor progression.

GcMAFplus: Science-Driven Immune Support

Scientific References

Weizmann Institute of Science: Master switch gene can turn immune cells into cancer eradicators ? Cancer Cell, 2025.

DOI: 10.1016/j.ccell.2025.03.021

Yamamoto et al.: GcMAF activates macrophages and increases phagocytic activity ? Anticancer Research, 2008.

Sinclair et al.: Transdermal immune modulators for tumor therapy ? Frontiers in Immunology, 2019. DOI:

10.3389/fimmu.2019.01043

At GcMAFplus, we are proud to lead in this field — providing clinically guided, laboratory-purified formulations that bridge cutting-edge science with practical immune support.